Inventor
STOCKLEY MARTIN LEE
GB24 patents
⚠️ This page may combine multiple inventors who share the name “STOCKLEY MARTIN LEE”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
MISSION THERAPEUTICS LTD
21 patentsUS9926307B2Mar 27, 2018
Compounds
MISSION THERAPEUTICS LTD14 citations92
US10392380B2Aug 27, 2019
Compounds
MISSION THERAPEUTICS LTD6 citations83
US11472798B2Oct 18, 2022
Compounds
MISSION THERAPEUTICS LTD1 citations72
US11130748B2Sep 28, 2021
Compounds
MISSION THERAPEUTICS LTD3 citations72
US10774078B2Sep 15, 2020
Compounds
MISSION THERAPEUTICS LTD2 citations72
US10640498B2May 5, 2020
Compounds
MISSION THERAPEUTICS LTD6 citations71
US11993595B2May 28, 2024
Compounds
MISSION THERAPEUTICS LTD0 citations62
US11958833B2Apr 16, 2024
Compounds
MISSION THERAPEUTICS LTD0 citations62
US11945797B2Apr 2, 2024
1-cyano-pyrrolidine derivatives as dub inhibitors
MISSION THERAPEUTICS LTD0 citations61
US11352339B2Jun 7, 2022
1-cyano-pyrrolidine derivatives as DUB inhibitors
MISSION THERAPEUTICS LTD0 citations61
US11236092B2Feb 1, 2022
Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (DUB) inhibitors
MISSION THERAPEUTICS LTD0 citations61
US10683269B2Jun 16, 2020
2-cyanoisoindoline derivatives for treating cancer
MISSION THERAPEUTICS LTD1 citations60
US11370784B2Jun 28, 2022
Cyano-substituted heterocycles with activity as inhibitors of USP30
MISSION THERAPEUTICS LTD0 citations51
US11091488B2Aug 17, 2021
1-cyano-pyrrolidine derivatives as inhibitors of USP30
MISSION THERAPEUTICS LTD0 citations51
US11084821B2Aug 10, 2021
Cyanopyrrolidine derivatives with activity as inhibitors of USP30
MISSION THERAPEUTICS LTD0 citations51
US11059809B2Jul 13, 2021
Substituted cyanopyrrolidines with activity as DUB inhibitors
MISSION THERAPEUTICS LTD0 citations51
US11014912B2May 25, 2021
Cyanopyrrolidine derivatives with activity as inhibitors of USP30
MISSION THERAPEUTICS LTD0 citations51
US10927110B2Feb 23, 2021
Cyano-subtituted heterocycles with activity as inhibitors of USP30
MISSION THERAPEUTICS LTD0 citations51
US10654853B2May 19, 2020
Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (DUB) inhibitors
MISSION THERAPEUTICS LTD0 citations51
US11414402B2Aug 16, 2022
Sulfonamide-substituted cyanopyrrolidines with activity as DUB inhibitors
MISSION THERAPEUTICS LTD0 citations50
US11306096B2Apr 19, 2022
4,6 dihydropyrrolo [3,4-C] pyrazole-5 (1H)-carbonitrile derivates for treating cancer
MISSION THERAPEUTICS LTD0 citations50